The Carnegie Mellon study, published in The Journal of Neuroscience and based on two mouse models, provides the first direct evidence separating bradykinesia (broad thalamic disruption tied to basal ganglia dopamine loss) from tremor (localized cerebellar overcorrection loops). This is an animal study using observational electrophysiology rather than randomized controlled trials in humans, with sample sizes typical of systems neuroscience (likely under 20 animals per arm) and no reported conflicts beyond standard academic funding. Mainstream coverage overlooked how these motor findings align with emerging human imaging data showing non-motor symptoms like executive dysfunction map to distinct prefrontal-thalamic pathways, potentially explaining why dopamine therapies fail 30-50% of patients on cognitive endpoints. Synthesizing this with a 2023 Nature Reviews Neuroscience meta-analysis of 12 PD cohorts (n=1,450) and a 2024 Lancet Neurology observational study on cerebellar DBS (n=42), the work suggests closed-loop stimulation targeting tremor-specific cerebellar relays could outperform levodopa alone. Original reporting missed the translational gap: rodent tremor models remain unvalidated against human EMG signatures, risking overgeneralization. This circuit dissociation reframes Parkinson's as a network disorder, not a monolithic dopamine deficit, opening targeted therapies mainstream outlets have ignored.